Addition to the Proposal to the Biotie Therapies Corp. Annual General Meeting convening on March 28, 2008

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE   March 26, 2008


Addition to the Proposal to the Biotie Therapies Corp. Annual General
Meeting convening on March 28, 2008

Biotie Therapies Corp. has received an amended proposal from
shareholders representing approximately 55% of shares and votes of
the Company for the composition of the Board of Directors to be
appointed at the Annual General Meeting to be held on 28 March 2008.
According to the proposal, the Board of Directors would comprise of
five members and that the current members (Mr. Juha Jouhki, Mr. Pauli
Marttila, Mr. Riku Rautsola and Mr. Piet Serrure) would be
re-appointed. In addition, Mr. Krish Krishnan would be appointed as a
Board member.

Mr. Krishnan has given his consent to his election.

Mr. Krishnan received a B.S. in Mechanical Engineering from the
Indian Institute of Technology (IIT), a M.S. in Engineering from the
University of Toledo, and an M.B.A. from The Wharton School at the
University of Pennsylvania.  Between March 2002 and February 2008,
Mr. Krishnan served as a Senior Managing Director of Third Security,
LLC., a venture capital and private equity firm. Concurrently, Mr.
Krishnan served as a member of the Board of Directors of  New River
Pharmaceuticals Inc. (NASDAQ:NRPH) between March 2003 and April 2007
and as its Chief Financial Officer and Chief Operating Officer
between April 2004 and April 2007.  He served as President and CEO of
Harvest Pharmaceuticals Inc. between February 2003 and April 2004.
Previously, Mr. Krishnan was involved with a start-up venture which
was sold to Ariba Technologies Inc., in August 2000. He then served
as a managing principal of Ariba, until joining Third Security, LLC
in March 2002. Mr. Krishnan was also a senior manager with A.T.
Kearney, Inc.; a consultant with KPMG Peat Marwick; and an engineer
with E.I. Dupont de Nemours.

March 26, 2008

Biotie Therapies Corp.
The Board of Directors


For further information, please contact:

Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com

www.biotie.com

Distribution:

OMX Nordic Exchange Helsinki
Main Media